Sage Journals: Discover world-class research

Abstract

Objective:

The objectives of this report were to characterize the regional and state differences in prescription methamphetamine and amphetamine distribution in the US.

Methods:

Prescription methamphetamine and amphetamine distribution was obtained from the Drug Enforcement Administration for 2019.

Results:

Total per capita drug weight distribution of amphetamine was 4,000 times higher than methamphetamine. Regionally, total per capita drug weight for methamphetamine was highest in the West (32.2% of total distribution) and lowest in the Northeast (17.4%). The total per capita drug weight for amphetamine was highest in the South (37.0% of total distribution) and lowest in the Northeast (19.4%). Distribution of methamphetamine was 16.1% while amphetamine was 54.0% of its production quota.

Conclusion:

Overall, prescription amphetamine distribution was common while prescription methamphetamine distribution was rare. The patterns observed in distribution are likely the result of stigmatization, differences in accessibility, and the efforts of initiatives such as the Montana Meth Project.

Keywords

stimulants Desoxyn Adderall XR

Get full access to this article

View all access options for this article.

References

Alvarado

H. A.

(2021). Telemedicine services in substance use and mental health treatment facilities (The CBHSQ Spotlight). Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/report/telemedicine-services

Anderson

D. M.

(2010). Does information matter? The effect of the meth project on meth use among youths. Journal of Health Economics, 29(5), 732–742. https://doi.org/10.1016/j.jhealeco.2010.06.005

Babicki

Arndt

Marcu

Liang

Grant

J. R.

Maciejewski

Wishart

D. S.

(2016). Heatmapper: Web-enabled heat mapping for all. Nucleic Acids Research, 44(W1), W147–W153. https://doi.org/10.1093/nar/gkw419

Blum

(2022). The hazards of prescribing A.D.H.D. drugs online. The New York Times. 2022. https://www.nytimes.com/2022/05/13/well/mind/cerebral-adhd-medication-tiktok.html

Bokhari

Mayes

Scheffler

R. M.

(2005). An analysis of the significant variation in psychostimulant use across the US. Pharmacoepidemiology and Drug Safety, 14(4), 267–275.

Bozinovic

McLamb

O’Connell

Olander

Feng

Haagensen

Bozinovic

(2021). U.S. National, regional, and state-specific socioeconomic factors correlate with child and adolescent ADHD diagnoses pre-COVID-19 pandemic. Scientific Reports, 11(1), 22008–8.

Chen

L. Y.

Strain

E. C.

Alexandre

P. K.

Alexander

G. C.

Mojtabai

Martins

S. S.

(2014). Correlates of nonmedical use of stimulants and methamphetamine use in a national sample. Addictive Behaviors, 39(5), 829–836. https://doi.org/10.1016/j.addbeh.2014.01.018

Coker

T. R.

Elliott

M. N.

Toomey

S. L.

Schwebel

D. C.

Cuccaro

Tortolero Emery

Davies

S. L.

Visser

S. N.

Schuster

M. A.

(2016). Racial and ethnic disparities in ADHD diagnosis and treatment. Pediatrics, 138(3), e20160407. https://doi.org/10.1542/peds.2016-0407

Dollar

C. B.

(2019). Criminalization and drug “wars” or medicalization and health “epidemics”: How race, class, and neoliberal politics influence drug laws. Critical Criminology, 27, 305–327. https://doi.org/10.1007/s10612-018-9398-7

10.

Drug Enforcement Administration Diversion Control Division. (2017). Pharmaceutical training seminars: UN reporting and quota section. Department of Justice Drug Enforcement Administration (p. 40). Retrieved January, 20 2023, from https://www.deadiversion.usdoj.gov/mtgs/pharm_train/conf_2017/april_2017/dang_2.pdf

11.

Drug Enforcement Administration Diversion Control Division. (2018). Established aggregate production quotas for Schedule I and II controlled substances and assessment of annual needs for the list I chemicals ephedrine, pseudoephedrine, and phenylpropanolamine for 2019. United States: Department of Justice Drug Enforcement Administration, 83(Number 248), 67348–67354. https://deadiversion.usdoj.gov/fed_regs/quotas/2018/fr1228.htm

12.

Drug Enforcement Administration Diversion Control Division. (2019). ARCOS drug retail summary reports. Department of Justice Drug Enforcement Administration (p. 385) Report No.: 01-07. Retrieved December, 8 2021, from https://www.deadiversion.usdoj.gov/arcos/retail_drug_summary/report_yr_2019.pdf

13.

Drug Enforcement Administration Diversion Control Division. (2020). Drug & Chemical Evaluation Section: Methamphetamine. Department of Justice Drug Enforcement Administration (p. 1). https://www.deadiversion.usdoj.gov/drug_chem_info/meth.pdf

14.

Epstein

J. N.

Loren

R. E.

(2013). Changes in the definition of ADHD in DSM-5: Subtle but important. Neuropsychiatry, 3(5), 455–458. https://doi.org/10.2217/npy.13.59

15.

Faraone

S. V.

(2018). The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neuroscience and Biobehavioral Reviews, 87, 255–270. https://doi.org/10.1016/j.neubiorev.2018.02.001

16.

Galbraith

(2015). The methamphetamine problem: Commentary on . . . psychiatric morbidity and socio-occupational dysfunction in residents of a drug rehabilitation centre. BJPsych Bulletin, 39(5), 218–220. https://doi.org/10.1192/pb.bp.115.050930

17.

Godfrey

Fuermaier

A. B. M.

Tucha

Butzbach

Weisbrod

Aschenbrenner

Tucha

(2021). Public perceptions of adult ADHD: Indications of stigma? Journal of Neural Transmission, 128(7), 993–1008.

18.

Gonzales

Mooney

Rawson

R. A.

(2010). The methamphetamine problem in the United States. Annual Review of Public Health, 31, 385–398. https://doi.org/10.1146/annurev.publhealth.012809.103600

19.

Hohman

J. A.

Martinez

K. A.

Anand

Martyn

Rood

Rothberg

M. B.

(2020). Use of direct-to-consumer telemedicine for attention-deficit hyperactivity disorder. Journal of General Internal Medicine, 35(11), 3392–3394.

20.

Hunt

Kuck

Truitt

(2006). Methamphetamine use: Lessons learned. National Institute of Justice (p. 76). Report No.: 209730. Retrieved Accessed January 20, 2022, from https://www.ojp.gov/pdffiles1/nij/grants/209730.pdf

21.

Karila

Weinstein

Aubin

H. J.

Benyamina

Reynaud

Batki

S. L.

(2010). Pharmacological approaches to methamphetamine dependence: A focused review. British Journal of Clinical Pharmacology, 69(6), 578–592. https://doi.org/10.1111/j.1365-2125.2010.03639.x

22.

Kish

S. J.

(2008). Pharmacologic mechanisms of crystal meth. Canadian Medical Association Journal, 178(13), 1679–1682. https://doi.org/10.1503/cmaj.071675

23.

Kooij

J. J.

Huss

Asherson

Akehurst

Beusterien

French

Sasané

Hodgkins

(2012). Distinguishing comorbidity and successful management of adult ADHD. Journal of Attention Disorders, 16(5 Suppl), 3S–19S. https://doi.org/10.1177/1087054711435361

24.

Livingston

J. D.

Milne

Fang

M. L.

Amari

(2012). The effectiveness of interventions for reducing stigma related to substance use disorders: A systematic review. Addiction, 107(1), 39–50. https://doi.org/10.1111/j.1360-0443.2011.03601.x

25.

Lopez

M. J.

Tadi

(2021). Drug enforcement administration drug scheduling. StatPearls Publishing. https://www.ncbi.nlm.nih.gov/books/NBK557426/

26.

Madera

J. D.

Ruffino

A. E.

Feliz

McCall

K. L.

Davis

C. S.

Piper

B. J.

(2022). Declines and pronounced state disparities in prescription opioid distribution in the United States. medRxiv. Advance online publication. https://doi.org/10.1101/2021.12.02.21266660.

27.

Mariani

J. J.

Levin

F. R.

(2007). Treatment strategies for co-occurring ADHD and substance use disorders. American Journal on Addictions, 16(Suppl 1), 45–56. https://doi.org/10.1080/10550490601082783

28.

Mariani

J. J.

Levin

F. R.

(2012). Psychostimulant treatment of cocaine dependence. Psychiatric Clinics of North America, 35(2), 425–439. https://doi.org/10.1016/j.psc.2012.03.012.

29.

McNeely

Arnsten

J. H.

Gourevitch

M. N.

(2006). Sterile syringe access and disposal among injection drug users newly enrolled in methadone maintenance treatment: A cross-sectional survey. Harm Reduction Journal, 3, 8. https://doi.org/10.1186/1477-7517-3-8

30.

Mueller

A. K.

Fuermaier

A. B.

Koerts

Tucha

(2012). Stigma in attention deficit hyperactivity disorder. Attention Deficit and Hyperactivity Disorders, 4(3), 101–114. https://doi.org/10.1007/s12402-012-0085-3

31.

Penley

Chen

H. H.

Eckel

S. F.

Ozawa

(2021). Characteristics of online pharmacies selling Adderall. Journal of the American Pharmaceutical Association, 61(1), e103–e109.

32.

Piper

B. J.

Ogden

C. L.

Simoyan

O. M.

Chung

D. Y.

Caggiano

J. F.

Nichols

S. D.

McCall

K. L.

(2018). Trends in use of prescription stimulants in the United States and Territories, 2006 to 2016. PLoS One, 13(11), e0206100.

33.

Recordati Rare Diseases Inc. (2015). Medication Guide: Desoxyn. United States: U.S. Food and Drug Administration (p. 16). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/005378s034lbl.pdf

34.

Salamanca

S. A.

Sorrentino

E. E.

Nosanchuk

J. D.

Martinez

L. R.

(2015). Impact of methamphetamine on infection and immunity. Frontiers in Neuroscience, 8, 445. https://doi.org/10.3389/fnins.2014.00445

35.

Siefried

K. J.

Acheson

L. S.

Lintzeris

Ezard

(2020). Pharmacological treatment of methamphetamine/amphetamine dependence: A systematic review. CNS Drugs, 34(4), 337–365. https://doi.org/10.1007/s40263-020-00711-x

36.

Steingard

Taskiran

Connor

D. F.

Markowitz

J. S.

Stein

M. A.

(2020). Correction to: New formulations of stimulants: An update for clinicians. Journal of Child and Adolescent Psychopharmacology, 29, 324–339. https://doi.org/10.1089/cap.2019.0043.correx

37.

Steinman

M. A.

Yang

K. Y.

Byron

S. C.

Maselli

J. H.

Gonzales

(2009). Variation in outpatient antibiotic prescribing in the United States. The American Journal of Managed Care, 15(12), 861–868.

38.

Sudakin

Power

L. E.

(2009). Regional and temporal variation in methamphetamine-related incidents: Applications of spatial and temporal scan statistics. Clinical Toxicology, 47(3), 243–247. https://doi.org/10.1080/15563650802516160

39.

US Census Bureau Geography Division. (2013). Census bureau regions and divisions with state FIPS codes. US Department of Commerce, Economics, and Statistic Administration (p. 2). Retrieved January 25, 2022, from https://www2.census.gov/geo/pdfs/maps-data/maps/reference/us_regdiv.pdf.

40.

Vaddadi

S. M.

Czelatka

N. J.

Gutierrez

B. D.

Maddineni

B. C.

McCall

K. L.

Piper

B. J.

(2021). Rise, and pronounced regional variation, in methylphenidate, amphetamine, and lisdexamfetamine distribution in the United States. PeerJ, 9, e12619.

41.

Volkow

N. D.

Fowler

J. S.

Wang

G. J.

Swanson

J. M.

Telang

(2007). Dopamine in drug abuse and addiction: Results of imaging studies and treatment implications. Archives of Neurology, 64(11), 1575–1579. https://doi.org/10.1001/archneur.64.11.1575

42.

Ward

J. A.

Zuckerman

Adams

C. A.

Napoli

(2011). Amphetamine use in Rhode Island Hospital trauma patients. The American Journal of Emergency Medicine, 29(5), 569–571. https://doi.org/10.1016/j.ajem.2011.02.026

43.

L. T.

John

W. S.

Morse

E. D.

Adkins

Pippin

Brooner

R. K.

Schwartz

R. P.

(2022). Opioid treatment program and community pharmacy collaboration for methadone maintenance treatment: Results from a feasibility clinical trial. Addiction, 117(2), 444–456. https://doi.org/10.1111/add.15641

44.

Strathearn

Liu

Yang

Bao

(2018). Twenty-year trends in diagnosed attention-deficit/hyperactivity disorder among US children and adolescents, 1997-2016. JAMA network open, 1(4), e181471.

45.

Ziller

E. C.

Anderson

N. J.

Coburn

A. F.

(2010). Access to rural mental health services: Service use and out-of-pocket costs. The Journal of Rural Health, 26(3), 214–224. https://doi.org/10.1111/j.1748-0361.2010.00291.x

46.

Zulauf

C. A.

Sprich

S. E.

Safren

S. A.

Wilens

T. E.

(2014). The complicated relationship between attention deficit/hyperactivity disorder and substance use disorders. Current Psychiatry Reports, 16(3), 436. https://doi.org/10.1007/s11920-013-0436-6

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.02 MB

Regional Disparities in Prescription Methamphetamine and Amphetamine Distribution Across the United States

Abstract

Objective:

Methods:

Results:

Conclusion:

Keywords

Get full access to this article

References

Supplementary Material